CD4 and cancer: Second, by turning the entire polyclonal population of CD4+ Tregs towards the tolerogenic pathway we can halt the immune response to cancer cells, viruses, pathogenic bacteria and other agents normally destroyed, so the next step will be the creation of antigen-specific iTregs.